Berkeley Lights to Participate in the 18th Annual PEGS Boston Conference & Expo

Rhea-AI Summary

Berkeley Lights (Nasdaq: BLI) announces participation in the 18th Annual PEGS Boston Conference, occurring from May 2-6, 2022. The company will present a new poster on a high-throughput workflow for TCR discovery and host two podium talks showcasing its Beacon® platform. Key presentations include:

• Poster P021: Focused on TCR discovery and live single T cell analysis.
• Podium Presentation on May 3: Discusses high-throughput visualization for therapeutic development.
• Podium Presentation on May 4: Outlines the OPBD 4.0 workflow for antibody discovery.

Company’s latest data to be presented on “Rapid High-Throughput Workflow for TCR Discovery on Solid Tumors with Functional Verification”

EMERYVILLE, Calif., April 29, 2022 (GLOBE NEWSWIRE) -- Berkeley Lights, Inc. (Nasdaq: BLI), a leader in digital cell biology, today announced its participation at the 18^th Annual PEGS Boston Conference, a protein engineering and cell therapy summit, being held virtually and in person from May 2-6, 2022 at the Hynes Convention Center.

Berkeley Lights’ participation this year includes a new, recently accepted poster presentation as well as two podium presentations. The Company will also feature its Beacon® platform technology and workflows in booth #514 for attendees to explore with hands-on demonstrations.

Additional information on Berkeley Lights’ presentations is below:

• Poster presentation P021: A Rapid High-Throughput Workflow for TCR Discovery on Solid Tumors with Functional Verification
  Abstract: Berkeley Lights will share new data on how the Berkeley Lights’ platform with Opto™ Cell Therapy Development Workflow allows for a multi-optics approach to study live, single T cells in culture. This technology paired with the workflow permits cells to stay alive, while probing protein production, cell-cell interactions, cytotoxicity, cell proliferation and downstream genomics analysis at the single cell level.
  
  
• Podium presentation: High-Throughput Visualization of Cell-Cell Interactions for Therapeutic Development Using the Berkeley Lights Platform on Tuesday, May 3, 2022 at 10 a.m. ET.
  Abstract: Berkeley Lights’ optofluidic platforms enable deterministic isolation and culturing of single or multiple cells in nanoliter-sized chambers, allowing for sequential functional assays on the same cell sample, thereby linking cytotoxicity and cytokine secretion. The Berkeley Lights R&D team recently demonstrated organoid structure formation on chip and is looking to use this capability in tumor microenvironment research.
  
  Podium presentation: Leave No Hit Behind: Accelerating Lead Molecule Discovery Against Difficult Targets on Wednesday, May 4 at 10 a.m. ET.
  Abstract: The Berkeley Lights’ Opto™ Plasma B Discovery (OPBD) 4.0 workflow enables recovery of 1000s of hits by screening up to 100,000 plasma cells, down-selection of lead candidates by functional screening, and sequencing and re-expression of >1000 functionally characterized antibodies in one week. By maximizing the diversity of antibodies through direct functional profiling of plasma cells, the OPBD 4.0 workflow allows users to tackle even the most challenging targets.

About Berkeley Lights 

Berkeley Lights is a leading digital cell biology company focused on enabling and accelerating the rapid development and commercialization of biotherapeutics and other cell-based products for our customers. The Berkeley Lights Platform captures deep phenotypic, functional, and genotypic information for thousands of single cells in parallel and can also deliver the live biology customers desire in the form of the best cells. Our platform is a fully integrated, end-to-end solution, comprising proprietary consumables, including our OptoSelect™ chips and reagent kits, advanced automation systems, and application software. We developed the Berkeley Lights Platform to provide the most advanced environment for rapid functional characterization of single cells at scale, the goal of which is to establish an industry standard for our customers throughout their cell-based product value chain. 

Forward-Looking Statements 

To the extent that statements contained in this press release are not descriptions of historical facts regarding Berkeley Lights or its products, they are forward-looking statements reflecting the current beliefs and expectations of management. Such forward-looking statements involve substantial known and unknown risks and uncertainties that relate to future events, and actual results and product performance could differ significantly from those expressed or implied by the forward-looking statements. Berkeley Lights undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties relating to the Company’s growth and continual evolution see the statements in the "Risk Factors" sections, and elsewhere, in our filings with the U.S. Securities and Exchange Commission.
 
Media Contact 
Media@berkeleylights.com 

Investor Contact 
IR@berkeleylights.com

FAQ

What will Berkeley Lights present at the PEGS Boston Conference?

Berkeley Lights will present a poster on a high-throughput workflow for TCR discovery and two podium presentations on therapeutic development and antibody discovery.

When is the PEGS Boston Conference taking place?

The PEGS Boston Conference is scheduled from May 2-6, 2022.

What is the focus of the poster presentation by Berkeley Lights?

The poster presentation focuses on a rapid high-throughput workflow for TCR discovery on solid tumors with functional verification.

What is the significance of the OPBD 4.0 workflow for Berkeley Lights?

The OPBD 4.0 workflow allows for the discovery of thousands of antibody candidates through the screening of up to 100,000 plasma cells.

Where can attendees find Berkeley Lights at the conference?

Attendees can explore the Berkeley Lights Beacon® platform and workflows at booth #514.